Congress must pass federal spending bills before December 20. Ensuring there is appropriated funding for the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH) is a critical piece of that. Both agencies play a key role in advancing therapies for cystic fibrosis – like the recently approved Trikafta – and robust funding is needed to continue their valuable efforts.
Despite so much progress in therapeutic treatments, we know now, more than ever, the most important and challenging work in CF is still ahead. Robust funding for the NIH and FDA will help us achieve our ultimate mission to find a cure for everyone living with CF.
